Mayflower Financial Advisors LLC Has $655,000 Position in Novo Nordisk A/S (NYSE:NVO)

Mayflower Financial Advisors LLC boosted its position in Novo Nordisk A/S (NYSE:NVO) by 13.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 7,613 shares of the company’s stock after buying an additional 894 shares during the quarter. Mayflower Financial Advisors LLC’s holdings in Novo Nordisk A/S were worth $655,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of NVO. Novare Capital Management LLC grew its holdings in Novo Nordisk A/S by 3.2% in the 3rd quarter. Novare Capital Management LLC now owns 2,727 shares of the company’s stock valued at $325,000 after buying an additional 85 shares in the last quarter. Rosenberg Matthew Hamilton boosted its position in shares of Novo Nordisk A/S by 2.5% in the third quarter. Rosenberg Matthew Hamilton now owns 3,812 shares of the company’s stock valued at $454,000 after acquiring an additional 94 shares during the period. Burns J W & Co. Inc. NY grew its stake in shares of Novo Nordisk A/S by 1.9% in the third quarter. Burns J W & Co. Inc. NY now owns 5,430 shares of the company’s stock valued at $647,000 after acquiring an additional 100 shares in the last quarter. Spinnaker Trust increased its position in Novo Nordisk A/S by 1.1% during the third quarter. Spinnaker Trust now owns 9,615 shares of the company’s stock worth $1,145,000 after acquiring an additional 100 shares during the period. Finally, Marco Investment Management LLC raised its stake in Novo Nordisk A/S by 1.5% in the 3rd quarter. Marco Investment Management LLC now owns 6,702 shares of the company’s stock worth $798,000 after purchasing an additional 100 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 1.3 %

Shares of NVO opened at $84.05 on Thursday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. Novo Nordisk A/S has a 52-week low of $78.17 and a 52-week high of $148.15. The firm has a market cap of $377.17 billion, a price-to-earnings ratio of 27.20, a PEG ratio of 0.90 and a beta of 0.45. The business’s fifty day moving average is $94.75 and its 200-day moving average is $114.02.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on NVO. StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. BMO Capital Markets reduced their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. Finally, UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.